A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer
A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer
This randomized phase III trial was originally designed to compare three different combination chemotherapy regimens to see how well they work. As of September 1, 2004, the study was expanded to a total of 6 arms (the original 3 arms (A, B, C) and 3 additional arms which were the same as the first 3 but with cetuximab) in treating patients who have undergone surgery for stage III colon cancer. Drugs used in chemotherapy, such as irinotecan hydrochloride, fluorouracil, leucovorin calcium, and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining more than one chemotherapy drug with monoclonal antibody therapy and giving them after surgery may kill any remaining tumor cells. It was not known at the time this study was developed which combination chemotherapy regimen is more effective after surgery in treating colon cancer. This study had several key changes, based on the results of other phase III trials. As of 6/1/2005, patients no longer received irinotecan on this study and treatment arms B, C, E, and F were discontinued. Patients on arms B and C crossed to arm A. Patients on arms E and F crossed to arm D. Patients on arms C and F who had not gotten to irinotecan continued on arms A and D, respectively. As of 8/18/2008, pre-screening for Kirsten rat sarcoma (KRAS) status was added with mutant KRAS (or KRAS not evaluable) patients put on arm G and wild-type KRAS patients randomized between arm A and arm D. Patients on arm G were treated per physician discretion and followed for disease and survival status. KRAS was determined in a central laboratory and was process for all patients on this study. The primary endpoint of this study was modified on 8/18/2008 to focus on patients having wild-type KRAS tumors. All modifications were approved by the Central Institution Review Board, local Institutional Review Boards, NCI, and the NCCTG Data Safety Monitoring Board.
PRIMARY OBJECTIVES:
I. Disease-free Survival (Arms A and D: Wild-type KRAS Patients)
SECONDARY OBJECTIVES:
I. Disease-free Survival (Arms A and D: Mutant KRAS Patients) II. Disease-free Survival III. Overall Survival IV. Toxicity
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to positive lymph node involvement (1-3 vs 4 or more), histology (high [poorly differentiated or undifferentiated] vs low [well to moderately differentiated]), and clinical T stage (T1 or T2 vs T3 vs T4). Patients are randomized to 1 of 6 treatment arms (as of 6/1/2005, patients are randomized to treatment arms I and IV only; arms II, III, V, and VI are closed to accrual). As of 8/18/2008, pre-screening for KRAS status was added with mutant KRAS (or KRAS not evaluable) patients put on arm G and wild-type KRAS patients randomized between arm A and arm D.
ARM A: Patients receive oxaliplatin intravenously (IV) over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46-48 hours on days 1. Treatment repeats every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
ARM B (closed to accrual as of 6/1/2005--currently enrolled patients may cross over to arm I for remainder of therapy): Patients receive irinotecan hydrochloride IV over 2 hours on day 1 and leucovorin calcium and fluorouracil as in arm A. Treatment repeats every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
ARM C (closed to accrual as of 6/1/2005--currently enrolled patients may cross over to arm I for remainder of therapy): Patients receive the same treatment as in arm A for 6 courses followed by the same treatment as in arm B for 6 courses (total of 12 courses). Treatment continues in the absence of unacceptable toxicity or recurrent disease.
ARM D: Patients receive cetuximab* IV over 1 hour on days 1 and 8 and oxaliplatin, leucovorin calcium, and fluorouracil as in arm A. Treatment repeats every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
ARM E (closed to accrual as of 6/1/2005--currently enrolled patients may cross over to arm D for remainder of therapy): Patients receive cetuximab* as in arm D and irinotecan hydrochloride, leucovorin calcium, and fluorouracil as in arm B. Treatment repeats every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
ARM F (closed to accrual as of 6/1/2005--currently enrolled patients may cross over to arm D for remainder of therapy): Patients receive cetuximab* as in arm D and chemotherapy as in arm C.
ARM G (added as of 8/18/2008, mutant KRAS (or KRAS not evaluable) patients): Locally directed therapy.
NOTE: *Cetuximab is administered over 2 hours at a higher dose on day 1 of course 1 only.
Quality of life (QOL) is assessed at baseline, 3 months, and at the end of therapy. As of 8/18/2008, QOL was discontinued.
Patients are followed for a maximum of 8 years from randomization.
Inclusion Criteria:
Histologically confirmed adenocarcinoma of the colon
No rectal cancer
Stage III tumor must have been completely resected within the past 56 days
At least 1 pathologically confirmed positive lymph node
Synchronous primary colon cancer allowed
No distant metastatic disease
Performance status - Eastern Cooperative Oncology Group (ECOG) 0-2
Absolute neutrophil count ≥ 1,500/mm^3
Platelet count ≥ 100,000/mm^3
Hemoglobin ≥ 9 g/dL
Bilirubin ≤ 1.5 times upper limit of normal (ULN)
Creatinine ≤ 1.5 times ULN
No uncontrolled high blood pressure
No unstable angina
No symptomatic congestive heart failure
No myocardial infarction with the past 6 months
No New York Heart Association class III or IV heart disease
No symptomatic pulmonary fibrosis
No symptomatic interstitial pneumonitis
No prior allergic reaction (known sensitivity) to chimerized or murine monoclonal antibody therapy
No known allergy to platinum compounds
No documented presence of human anti-mouse antibodies (HAMA)
No active uncontrolled bacterial, viral, or systemic fungal infection
HIV negative
No clinically defined AIDS
Not pregnant or nursing
Negative pregnancy test
No men or women of childbearing potential who are unwilling to employ adequate contraception
No inadequately treated gastrointestinal bleeding
No ≥ grade 2 pre-existing peripheral sensory or motor neuropathy
No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or lobular carcinoma in situ in 1 breast
No other concurrent medical condition that would preclude study participation
No concurrent biologic therapy
No prior chemotherapy for colon cancer
No other concurrent chemotherapy
No prior radiotherapy for colon cancer
No concurrent targeted agents
No prior agents directed against epidermal growth factor-receptor
No other concurrent anticancer therapy
San Diego, California 92161, United States
San Francisco, California 94115, United States
San Pablo, California 94806, United States
Washington D.C., District of Columbia 20057, United States
Jacksonville, Florida 32207, United States
Orange Park, Florida 32073, United States
Fort Wayne, Indiana 46845, United States
Ann Arbor, Michigan 48106, United States
Springfield, Missouri 65802, United States
East Orange, New Jersey 07018-1095, United States
Mount Holly, New Jersey 08060, United States
New York, New York 10025, United States
Harrisburg, Pennsylvania 17110, United States
Philadelphia, Pennsylvania 19104, United States
Scranton, Pennsylvania 18508, United States
Sioux Falls, South Dakota 57117-5134, United States
San Antonio, Texas 78229, United States
Yakima, Washington 98902, United States
Eau Claire, Wisconsin 54703, United States
Saint John, New Brunswick E2L 4L2, Canada
Greater Sudbury, Ontario P3E 5J1, Canada
Charlottetown, Prince Edward Island C1A 8T5, Canada